---
title: "SDIC Capital: The application for the issuance of no more than 4 billion yuan of renewable corporate bonds to professional investors has been approved"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/245282111.md"
description: "On the evening of June 19th, SDIC Capital announced that its registration application for the public issuance of perpetual corporate bonds with a total face value of no more than 4 billion yuan to professional investors has been approved by the China Securities Regulatory Commission"
datetime: "2025-06-19T12:07:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/245282111.md)
  - [en](https://longbridge.com/en/news/245282111.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/245282111.md)
generator: "portal-rs"
---

# SDIC Capital: The application for the issuance of no more than 4 billion yuan of renewable corporate bonds to professional investors has been approved

On the evening of June 19, SDIC Capital announced that its application for the public issuance of perpetual corporate bonds with a total face value of no more than 4 billion yuan to professional investors has been approved by the China Securities Regulatory Commission

### Related Stocks

- [600061.CN](https://longbridge.com/en/quote/600061.CN.md)

## Related News & Research

- [Beijing State-Owned Capital Operation targets “full-cycle, multi-asset” fund platform in 15th Five-Year plan draft](https://longbridge.com/en/news/297650698.md)
- [Great-West’s Empower closes purchase of Milliman pension administration business](https://longbridge.com/en/news/297783114.md)
- [15:34 ETIgnyte Insurance Acquires InsureMyTrip](https://longbridge.com/en/news/297690224.md)
- [Earth Science Tech, Inc. Announces 2026 Annual Shareholder Meeting Results | ETST Stock News](https://longbridge.com/en/news/297687527.md)
- [NeuroThera Labs seeks FDA orphan drug status for adult Tourette treatment SCI-110](https://longbridge.com/en/news/297783543.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**